Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL
Bengaluru (Karnataka) [India], June 19: Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)--a global authority in analytical science--has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-approved approach for detecting aloins--reinforcing safety and quality benchmarks across botanical and dietary supplement industries. Certified Method Enhances Global Botanical Quality and Safety.
Developed by Herbalife scientists and validated by independent laboratories worldwide, this AOAC-certified method is used to test every batch of Herbalife's aloe-based products, ensuring safety, while preserving aloe vera's natural benefits. Aloe vera is a key ingredient in many of Herbalife's top products, which are sold in more than 90 markets.
"This AOAC validation is an important milestone for Herbalife and the industry as a whole," said Gary Swanson, SVP of Global Quality at Herbalife and lead author of the study. "We are proud to lead scientific innovation that enhances botanical ingredient safety, benefitting not only Herbalife products and our customers, but also advancing standards across the industry."
Herbalife's method was validated through a global multi-laboratory study involving eight independent laboratories. Each lab tested the same set of six aloe vera samples, including both raw materials and finished products, using HPLC (High-Performance Liquid Chromatography) to measure aloin A, aloin B, and aloe-emodin. The study ensured the method's accuracy and reliability across various labs and product types, with results confirming that it met all performance criteria, including precision and system suitability.
"This multi-laboratory validation study supported approval of an analytical method developed by Herbalife scientists as the AOAC 2016.09 Official Final Action Method," said Dr. Katerina Mastovska, deputy executive director and chief science officer, AOAC INTERNATIONAL. "AOAC official methods undergo rigorous scientific evaluation and are highly credible and globally accepted. As such, this method will help strengthen botanical quality and safety standards worldwide."
Herbalife has a long-standing commitment to aloe vera research and quality assurance. This dedication has resulted in five patents and three published studies focused on developing safe extraction methods that preserve the plant's natural benefits. While many companies rely solely on supplier certifications to confirm the authenticity of their aloe vera, Herbalife goes further. The company is one of the few in the world using advanced proton nuclear magnetic resonance (NMR) spectrometry--an analytical technique that uses magnetic fields and radio waves to identify the molecular structure of raw materials. This allows Herbalife to independently verify the identity and purity of its aloe vera at the molecular level, ensuring the highest standards of quality, consistency and traceability across its global supply chain.
For 45 years, Herbalife has upheld a global commitment to quality through its rigorous Seed to Feed process. This comprehensive system ensures that every ingredient--from responsibly sourced crops cultivated by dedicated farmers to the finished product--meets stringent standards for identity, potency, safety, and purity. Herbalife performs internal testing in ISO 17025-accredited laboratories, verifying that ingredients comply with both company standards and government regulations. The company's science-backed approach, grounded in Good Manufacturing Practices (GMPs) and NSF International standards, delivers consistent, transparent products in more than 90 markets. Supported by a global team of scientists and quality experts, this process strengthens consumer trust and continues to advance industry standards worldwide.
Herbalife's aloe vera testing method has been published in Journal of AOAC INTERNATIONAL (Volume 108, Issue 3, Pages 449-471).
About Herbalife Ltd.
Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit https://ir.herbalife.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
27 minutes ago
- Economic Times
Ditch your glasses - breakthrough eye drops approved by FDA to fix your near vision instantly
Vizz, a new FDA-approved eye drop, offers adults with age related near vision loss (presbyopia) a daily, non-surgical solution. Developed by Lenz Therapeutics, it works by gently shrinking the pupil to help focus on nearby objects. Backed by clinical trials, Vizz acts within 30 minutes and lasts up to 10 hours, offering freedom from reading glasses for millions. Tired of too many ads? Remove Ads Strong clinical results with minimal side effects A modern alternative for aging eyes Tired of too many ads? Remove Ads FAQs: In a major medical breakthrough, the U.S. Food and Drug Administration has approved Vizz , a once daily eye drop that helps improve near vision without the need for reading glasses. Created by Lenz Therapeutics , Vizz is the first eye drop to use aceclidine, a compound that temporarily reduces pupil size to sharpen close up eye drop works by creating a mild "pinhole effect" that extends the eye's depth of focus, improving the ability to see things up close. Vizz is fast acting, with noticeable improvement in vision within 30 minutes, and the benefits can last for up to 10 hours with just one drop a was approved after being tested in three major Phase 3 trials CLARITY 1, 2, and 3. These studies involved hundreds of participants over several weeks and months. Results showed that a majority of users gained a three-line improvement in near vision on a standard eye chart, a strong indicator of more reassuring, the safety profile was excellent. No serious side effects were reported. A small number of users experienced mild symptoms like eye irritation, headache, or dim vision, but these effects were temporary and resolved without treatment. Importantly, Vizz did not negatively affect distance vision, making it practical for everyday could be a game changer for the estimated 128 million Americans living with presbyopia . Rather than relying on glasses or surgical options, patients now have access to a non-invasive, convenient treatment they can use daily. The drops are expected to be available in the U.S. by late 2025, starting with sample distributions in doctors' approval marks a turning point in eye care innovation. With its fast results, strong safety data, and ease of use, Vizz offers new hope to people who want to regain near vision clarity and reduce their dependence on corrective lenses.A1. Presbyopia is a common condition where the eye's lens loses flexibility, making it hard to focus on close-up objects. It typically starts after the age of 40.A2. As we age, the lens inside the eye becomes less flexible. This makes it harder for the eye to adjust and focus on close objects.
Time of India
3 hours ago
- Time of India
Donald Trump's tariff tussle: Duties on Indian pharma would be 'counterproductive'; America may take at least 3 years to match India's scale, says Pharmexcil
US President Donald Trump imposed an additional 25% tariff on Indian imports on the top of an already existing 25% duty, pushing the total to 50%. These high tariffs, announced on August 6, would take effect from August 27. The pharmaceutical sector, however, received a temporary exemption from the tariff hike, highlighting India's crucial role in ensuring affordable access to medicines for millions of Americans. Responding to the development, the Pharmaceutical Export Promotion Council (Pharmexcil) said the exemption reinforces India's position as a vital player in global healthcare. 'Tariffs on Indian pharma would be counterproductive, ultimately burdening American consumers. Indian companies manufacture low-cost generics—not high-margin products—so any tariff costs would pass directly to US consumers,' Pharmexcil chairman Namit Joshi said in a statement quoted by PTI. The US gets over 40% of generic medicines from India. These includes vital treatments for cancer, chronic illnesses, and infectious diseases. Joshi further warned that attempting to replicate India's pharmaceutical infrastructure would take at least 3 to 5 years and come with major hurdles in scale, cost-effectiveness, and skilled manpower. 'With over 700 US FDA-approved facilities and 12 per cent of industry earnings reinvested in compliance, India exports 55 per cent of its pharma products to tightly regulated markets like the US, UK and EU, a testament to its unmatched quality standards,' he added. Pharmexcil has urged both governments to maintain cooperation in order to protect the integrity of the global pharmaceutical supply chain. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), also confirmed that the US administration's latest executive order exempts the pharma sector from immediate tariff imposition. 'Generic medicines are important for affordable healthcare in the US and typically operate on razor-thin margins. Ensuring their consistent availability is critical for patient care,' Jain noted. He also explained that the sector remains under review, pending the outcome of an investigation under Section 232 of the Trade Expansion Act of 1962. Stay informed with the latest business news, updates on bank holidays and public holidays .
Time of India
6 hours ago
- Time of India
Can India's SME Exchanges catalyse a K-shaped economic revolution?
Live Events The global economy is enduring a K-shaped recovery, where divergence defines progress, some sectors surge ahead on innovation and adaptability while others stagnate under legacy burdens. For emerging markets like India, this uneven trajectory presents both a challenge and an the challenges are clear, the opportunities revolve around an underappreciated lever of economic transformation: alternative stock exchanges specifically for small and medium enterprises (SMEs). India's NSE and BSE are not just financial conduits but engines that drive the country's economic growth no doubts there. However, a crucial question emerges: can they move beyond their niche status to support SMEs, while also mitigating differences during a K-shaped recovery?Globally, alternative exchanges have repeatedly proven their ability to democratise capital and fuel economic dynamism. The Nasdaq, launched in 1971 as an electronic counter to the NYSE's rigid floor trading model, became the launchpad for tech visionaries Apple, Microsoft, and Amazon who might have struggled under traditional listing norms. Similarly, London's AIM market, operational since 1995, has propelled over 3,800 SMEs into the limelight, collectively raising more than £130 billion in growth capital. What makes these platforms succeed is their ability to lower barriers regulatory, financial, and operational that traditionally exclude smaller, high potential firms from mainstream the West, Asia offers compelling precedents. Hong Kong's Growth Enterprise Market (GEM), established in 1999, was designed to support high growth startups, particularly in tech and innovation driven sectors. Though it faced challenges including liquidity constraints and regulatory scrutiny it played a pivotal role in nurturing early-stage firms before they graduated to the main board. Similarly, Japan's Mothers Market (Market of the High growth and Emerging Stocks), launched in 1999 under the Tokyo Stock Exchange, has been instrumental in funding disruptive ventures, particularly in robotics, biotech, and green energy. Even China's ChiNext (2009) and STAR Market (2019), though more structured than pure SME exchanges, have demonstrated how tailored listing ecosystems can accelerate innovation by connecting high growth firms with patient too, is witnessing a quiet revolution through exchanges like the Cape Town Stock Exchange (CTSE) and A2X, which focus on agile, high growth sectors insulated from broader economic sluggishness. The common thread across these platforms is their recognition that uneven recoveries demand uneven solutions markets that prioritise agility over scale, and innovation over this global backdrop, India's SME exchanges BSE SME (2012) and NSE Emerge (2012) present a fascinating case study. In their very first decade, they have facilitated close to 1,000 SME IPOs , collectively raising approximately ₹30,000+ crores (~$3.6 billion). The momentum is accelerating: 2023 saw a record 182 SME IPOs, a 50% year-on-year surge, reflecting growing confidence among entrepreneurs and investors alike. More strikingly, the BSE SME IPO index delivered ~60% returns in 2023, dwarfing the ~20% gains of the Nifty 50. High growth sectors Fintech, specialty chemicals, electric vehicle components, and advanced manufacturing dominate these listings, underscoring the platform's role in funding India's next gen for all their promise, India's SME exchanges remain hamstrung by structural inefficiencies. Liquidity is a persistent challenge low free float and scant institutional participation lead to erratic trading volumes, forcing many firms to eventually migrate to mainboard listings. Regulatory burdens, particularly post listing compliance costs, remain disproportionately high for small enterprises. And despite rising retail interest evident in SME IPOs being oversubscribed 100x or more there remains a trust path forward demands bold, systemic interventions and recent regulatory evolution suggests India is laying the groundwork for meaningful change. Institutional participation must deepen, with mutual funds, alternative investment funds (AIFs), and foreign portfolio investors (FPIs) needing stronger incentives to bring stability and liquidity to SME stocks. Market making mechanisms require strengthening to curb volatility, while regulatory refinements must continue to make these platforms more accessible without compromising governance. The growing focus on financial literacy for both entrepreneurs exploring IPO avenues and investors navigating risk perceptions is particularly crucial, when government-backed awareness campaigns combine with incubators and investment banks guiding SMEs on IPO readiness, we see the emergence of a more robust ecosystem. These developments, coupled with progressive regulatory adjustments, are gradually transforming SME exchanges from high-risk niches into structured growth engines precisely what India needs to harness its entrepreneurial potential in this era of economic most importantly, India should explore sector specialized SME boards dedicated platforms for agri-tech, clean energy, and deep-tech ventures that align with the nation's strategic priorities. Imagine an "Emerge Green" board for sustainable startups or an "Emerge Tech" platform for AI and semiconductor innovators. Such focused ecosystems could replicate the success of China's STAR Market, which fast tracked listings for tech and biotech firms, or Japan's Mothers Market, which became a hotspot for robotics and automation stakes could not be higher. In a K-shaped world, where economic fortunes diverge sharply, India's SME exchanges offer a rare convergence of growth and inclusion. They can ensure that the smallest firms with the biggest ideas aren't left behind but instead become the drivers of India's next economic leap. The global precedents are clear, and the early signs are encouraging. The challenge now is for India's policymakers and market participants to carry this momentum forward or risk letting a crucial opportunity slip emergence of SME exchanges is more than a market development; it's a structural necessity for India's economic resilience and grassroots capital formation. For India to harness its entrepreneurial energy and navigate the K-shaped recovery, these platforms must evolve from niche curiosities to mainstream catalysts. The world has shown it's possible. The numbers suggest it's plausible. The only uncertainty is whether India will make it writer is MD and Founder, Highbrow Securities.
